Last reviewed · How we verify
NCT07211373: ASSIST
Advancing Student Suicide Interventions With Scalable Technologies
NA trial testing Jaspr in Suicidal Ideation in 50 participants. Enrolling by invitation.
30 June 2027
Quick facts
| Lead sponsor | University of Massachusetts, Amherst |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 8 October 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Jaspr
- Behavioral support
Conditions studied
- Suicidal Ideation — all drugs for Suicidal Ideation →
- Suicide Attempt — all drugs for Suicide Attempt →
- Self-Harm — all drugs for Self-Harm →
Sponsor
University of Massachusetts, Amherst
Who can join
18 and older, any sex, with Suicidal Ideation or Suicide Attempt. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mobile-based applications, such as JasprHealth, can deliver evidence-based skills intended to reduce imminent suicide risk (e.g., reducing means access), improve emotional states (e.g., via distraction and coaching to act opposite to emotions), and reduce feelings of social isolation (e.g., via shared stories), but user engagement is a barrier. The aim of this study was to examine the effects of a technological application resource (Jaspr) relative to human augmentation (Jaspr+, e.g., motivationally focused orientation plus prompts) on acceptability, preliminary effectiveness, and engagement among college students who screen positive for suicide risk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07211373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Suicidal Ideation
Currently open trials in the same condition.
- NCT07438912 — Mind After Midnight · NA · recruiting
- NCT07238192 — Augmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD · NA · recruiting
- NCT07217444 — Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation · NA · recruiting
- NCT07259408 — Co-creation of Tools for People in Detention With Suicidal Thoughts and/or Behavior · recruiting
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
Other University of Massachusetts, Amherst trials
Trials by the same sponsor.
- NCT06990997 — Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia · NA · recruiting
- NCT07016555 — Burning Mouth Syndrome: Symptoms and Management · EARLY_PHASE1 · recruiting
- NCT06412016 — Urban Gardening and Peer Nutritional Counseling for People With HIV and Food Insecurity · NA · active not recruiting
- NCT06399939 — The Function of Biphasic Sleep in Infants · NA · recruiting
- NCT05949866 — Feasibility and Fidelity of a Gross Motor-based Physical Activity Intervention on Cognition in Preschool-age Children · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07211373 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Amherst
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07211373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing